SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Songjiang sold a total of 2,216 shares of common stock over two days, with transactions occurring on January 6 and January 7, 2025. The sales come as GYRE shares have declined 17% in the past week, according to InvestingPro data.
The sales were executed under a pre-established trading plan, with the shares sold at weighted average prices ranging from $10.02 to $10.16 per share. The total value of these sales amounted to approximately $22,336. The stock currently trades at $9.62, with InvestingPro analysis indicating the shares are trading above their Fair Value.
Following these transactions, Songjiang now indirectly owns 2,916,251 shares, held by his spouse. These transactions were carried out under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks in compliance with insider trading laws. The $827 million market cap company maintains a strong financial position with a current ratio of 3.72, though it remains unprofitable over the last twelve months. InvestingPro subscribers can access 7 additional key insights about GYRE’s financial health and valuation metrics.
In other recent news, Gyre Therapeutics has seen several significant changes in its leadership. The biotechnology firm recently appointed Ping Zhang as the lead independent director of its Board of Directors. In addition to his board role, Zhang will serve on the Nominating and Corporate Governance Committee. Zhang brings a wealth of financial expertise from his current position as a Managing Partner at String Capital Management and previous roles at AEON Life Insurance (NS:) Company and Japan Asia Investment Co.
Simultaneously, at Gyre’s indirectly owned subsidiary, Gyre Pharmaceuticals, Ying Luo stepped down as Chairman, with Songjiang Ma stepping into the role. These developments are part of the recent changes within the company.
In terms of financials, Gyre Therapeutics reported a gross profit margin of 96.23% with total revenues of $105.03 million in the last twelve months. Its subsidiary, Gyre Pharmaceuticals, is making strides in the People’s Republic of China, including ongoing clinical trials for F351 and the commercialization of ETUARY® (Pirfenidone capsule), which reported 2023 net sales of $112.1 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
